Amit Etkin, MD, PhD, the CEO of Alto Neuroscience, discusses the unaddressed issue of cognitive impairment in schizophrenia, and how Alto's treatment in development could be a solution for patients in need. Cognitive impairment is massive. Dr Etkin is cofounder and CEO of Alto Neuroscience, and a professor of psychiatry and behavioral sciences at Stanford University. Alto Neuroscience announces robust replication of EEG biomarker to objectively identify patients with cognitive impairment in schizophrenia. Kuntz L. Theta-band responses: the EEG biomarker to objectively identify patients with cognitive impairment in schizophrenia.